The Health Research Authority (HRA) protects and promotes the interests of patients and the public in health research. HRA is an executive non-departmental public body, sponsored by the Department of Health and Social Care.

The role plays an important part in protecting the rights, safety, dignity and well-being of research participants, while facilitating and promoting ethical research for the benefit of society. As leader of the committee, Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research, and clear decisions are made and recorded.

Keith Berelowitz said of the appointment:

“Ethics committees and the roles they perform in safeguarding patients involved in research are a vital part of our industry. I joined an ethics committee to give a little back and to expand my knowledge of academic and commercial clinical research, so, for me to take on this role as Chair for the Fulham Research Ethics Committee is an opportunity to continue that journey.”

We would like to take the opportunity to congratulate Keith on his appointment to the role of Committee Chair. His experience, knowledge and passion for patient safety and clinical trial operations will be invaluable to the Health Research Authority’s strategy for health across the UK.

Latest news

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Unlocking the potential of data sharing

January 4, 2023
Dilshat Djumonov explores how GDPR is central to protecting private information while presenting unique challenges to the pharmaceutical clinical trials industry.
Read more


13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event